News

PharmExec13h
FDA Accepts GSKs NDA for First-in-Class IBAT Inhibitor Linerixibat to Treat Cholestatic Pruritus in Primary Biliary Cholangitis
New drug application submission was based on positive data from the Phase III GLISTEN trial, which demonstrated significant ...
PharmExec12h
FDA Approves Bayer’s Nuqeba for Metastatic Castration-Sensitive Prostate Cancer
Approval was based on results from the Phase III ARANOTE trial, in which Nubeqa demonstrated a 46% reduction in the risk of ...
PharmExec21h
Navigating Funding Cuts and Unpredictable Tariffs: Q&A with Darius Lakdawalla, PhD
The industry is facing challenges from the new administration that could have serious impacts on everything from market ...